Quotient Therapeutics and Merck have entered a multi-year research collaboration to discover novel drug targets in inflammatory bowel disease using Quotient's somatic genomics platform. Cambridge, Massachusetts-based Quotient will apply its computational genomics technology to interrogate patient tissue for naturally occurring somatic mutations linked to IBD. Merck, known as MSD outside the US and Canada, will gain access to targets identified through the platform for downstream drug development and commercialization. The deal was announced on March 24, 2026.
Under the terms of the agreement, Quotient will receive an upfront payment of USD 20 million. The company is eligible for development, regulatory, and commercial milestones totaling up to USD 2.2 billion. Royalty terms were not disclosed. No equity component was described in the announcement. The milestone total likely reflects payments aggregated across multiple potential target programs rather than a single asset, consistent with the multi-target discovery scope of the collaboration. Per-program milestone breakdowns and option exercise fees, if any, were not disclosed.
Deal context
The somatic genomics platform operates on the principle of somatic mosaicism. Human cells accumulate spontaneous genetic mutations over a lifetime, creating trillions of distinct genomes within a single individual. Quotient's technology sequences patient tissue to catalog these mutations and computationally links them to disease phenotypes. The approach aims to identify genes that, when mutated in tissue, causally drive or protect against disease. This differs from genome-wide association studies, which rely on inherited germline variants and population-level statistical associations to identify risk loci. Quotient's method instead uses tissue-level somatic variation as an endogenous perturbation screen in living patients.
No specific biological target, drug modality, or molecule is associated with this collaboration. The work sits at the target identification stage, upstream of hit finding, lead optimization, or preclinical development. No clinical trials are registered for any asset derived from the platform. Quotient, founded by Flagship Pioneering in 2022, has not disclosed named drug candidates from prior platform applications.
IBD encompasses Crohn's disease and ulcerative colitis. Existing therapies include anti-TNF agents, JAK inhibitors, anti-integrins, and IL-23 inhibitors. Marc Levesque, Vice President of Discovery at Merck Research Laboratories, noted in the announcement that no disease-modifying treatments are currently available for IBD. Merck has identified immunology as a priority therapeutic area. The collaboration positions Quotient's platform as a tool to uncover novel IBD drug targets that existing genetic approaches may have missed.